Muted performance in US and Ex-US generics and one-off write-off of Aleor's Intangible assets, tumbles sales and profit | Alembic Pharmaceuticals Q1 FY23 Result & Earning Call Highlights

Alembic Pharma had a bad quarter with muted performance in US generic, Ex-US and Indian business. The decline in YoY basis was registered as the same quarter had covid related drugs sales while in this quarter the sales of the same are muted.